VIVEbiotech, S.L., a gene transfer technologies CDMO developing and manufacturing lentiviral vectors, is opening new facilities for the manufacture of lentiviral vectors for the cell and gene therapy sector. The facility will be capable of manufacturing batches ranging from those for early stage research to GMP for clinical and future commercial uses.
 
The expanded facilities will allow the company to significantly increase its production capacity and deliver commercial-size batches of lentiviral vectors to both new and existing customers across the cell and gene therapy industry. VIVEbiotech’s production capacity will increase by 400%, with an increase in average batch size per year from 20 in 2020 to 80 in 2022. VIVEbiotech will also be able to broaden its product portfolio, and scale its delivery of products for all phases of clinical trial and commercialization.
 
VIVEbiotech will install the largest bioreactor currently available on the global market, with seven cleanrooms set up specifically for lentiviral-vector manufacturing. Versatility in the design will result in a more flexible configuration enabling the possibility of further clean rooms in the future as well as making it feasible accommodating a much larger number of batches.
 
VIVEbiotech has also expanded other key departments including R&D, upstream and downstream process development departments, and is expanding its workforce to 85 employees by the end of 2021.